RT Journal Article
SR Electronic
T1 Treatment and Cost -outcomes of a simplified antiretroviral treatment strategy for hepatitis C among HCV and HIV co-infected patients in Ukraine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253780
DO 10.1101/2021.03.19.21253780
A1 Sergie Antoniak
A1 C Charles Chasela
A1 Morgan J Freiman
A1 Yulia Stopolianska
A1 Tetiana Barnard
A1 MM Gandhi
A1 Maria Liulchuk
A1 Zhanna Tsenilova
A1 V Tretiakov
A1 Jeri Dible
A1 Constance Wose Kinge
A1 T Minior
A1 Sofiane Mohamed
A1 Fadzai Marange
A1 Clint Cavenaugh
A1 Charles van der Horst
A1 Svitlana Antonyak
A1 Thembisile Xulu
A1 Kara W Chew
A1 Ian Sanne
A1 Sydney Rosen
A1 for EQUIP Health
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.19.21253780.abstract
AB Background We conducted a demonstration project of an integrated HIV and viral hepatitis testing and treatment strategy using generic ledipasvir/sofosbuvir (LDV/SOF).Methods Eligible HCV viraemic adults from two clinics in Kyiv were treated with LDV/SOF +/-weight-based ribavirin for 12 weeks. Clinical assessments were performed at screening and week 24 and as needed; treatment was dispensed every 4 weeks. The primary outcome was sustained virologic response (SVR)12 weeks after treatment. Program costs in 2018 USD were estimated per patient treated using observed resource utilization, local unit, and antiretroviral therapy (ART) costs over the 24-week period.Results 868 participants initiated on treatment, 87% (755) were PWID and 55.5% (482) were HIV co-infected. The common genotypes were 1 (74.1%) and 3 (22%) and SVR was achieved in 831/868 (95.7%) by intention-to-treat analysis. The average cost per patient treated was $680, assuming generic LDV/SOF and ribavirin pricing and standard quantitative HCV viral load testing. Medications comprised 38% of the average cost/patient, laboratory tests 26%, events (clinic visits, counselling) 10%, and indirect costs 26%. ART accounted for 60% of all drug costs, with HCV medications just 40%.Conclusion Generic LDV/SOF +/- ribavirin provided produced exceptionally good outcomes including amongst patients with genotype 3 HCV and PWID at an average cost of <$700/patient year, including ART for those with HIV. Under the assumptions of generic drug pricing but higher laboratory costs, an average cost of $750/patient is likely a reasonable estimate for this intervention in Ukraine, excluding costs for scaling or maintaining the treatment program.Competing Interest StatementK.W.C. has received a research grant to the institution from Merck Sharpe & Dohme. The other authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.Clinical TrialNCT04038320Funding StatementUSAID EQUIP Grant No AID OAA A 1500070 Non-pharmaceutical industry funds Luxemburg Business Partnership Facility 2017, Grant No MAE/014 17 1620Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ukrainian Institute on Public Health Policy IRB #1, Institutional Review Board (00007612) and the University of the Witwatersrand Human Research Ethics Committee (M17078). The Boston University Institutional Review Board approved the analysis of a de-identified analytic dataset (H-37820).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request